Charles Cherington's most defensible net worth estimate falls somewhere between $28 million and $71 million, with the most credible anchor sitting closer to the $30–50 million range when you factor in his documented equity stakes, private equity career compensation, and conservation land holdings. The wide spread between those public estimates is a product of how differently traceable his assets are: some are tied to publicly reported SEC filings, while the bulk of his wealth (private equity fund economics) is largely invisible to outside observers. Here's what the evidence actually shows.
Charles Cherington Net Worth: Estimate, Sources, and Key Drivers
First: Make Sure You Have the Right Charles Cherington
This is genuinely important because the name Charles R. Cherington has appeared in public records across at least three distinct people. The one most people searching today are looking for is Charles Reed Cherington, the private equity investor and managing partner based in Belmont, Massachusetts. He co-founded Ara Partners in 2017 alongside Troy Thacker, previously founded Intervale Capital in 2006, and shows up in SEC filings as a 10% owner of Eterna/Ernexa Therapeutics (ticker: ERNA). He holds a BA in History from Wesleyan University and an MBA with honors from the University of Chicago.
Who he is not: A Harvard Crimson obituary from 1967 documents a different Charles R. Cherington, described as an expert in industry and government regulation who died at age 53. There's also a separate Wesleyan archival entry for a 'Charles R. Cherington, 1954' that shows up in academic records. Neither of those is the private equity Cherington generating the modern net worth searches. If you landed here after seeing his name in an SEC filing or an Ara Partners press release, you've got the right person.
Estimated Net Worth Range and What It Covers

Two credible aggregator platforms put the number in very different places. Benzinga estimates his net worth at $71.1 million (last updated May 19, 2026), while QuiverQuant places it at 'at least $28.1 million' as of May 6, 2026. Both derive their figures primarily from his disclosed equity holdings in Eterna/Ernexa Therapeutics, which are the only assets that show up cleanly in public SEC filings. The Benzinga figure is higher partly because it likely incorporates a broader interpretation of beneficial ownership (including options, warrants, or convertible instruments), while QuiverQuant's floor number reflects only directly owned common shares. Neither figure captures his private equity compensation, real estate, or conservation land holdings in Vermont, which means both numbers should be treated as minimums rather than totals. If you're trying to pin down Don Charlton net worth, be aware that private equity and other non-public assets can make published estimates misleading.
A more complete estimate, accounting for career-stage compensation typical of a managing partner at a firm that closed a $400 million fund, probable carried interest accumulation over 25+ years across ten private equity firms, and his status as Vermont's largest private owner of conservation land, would reasonably push the true figure higher. A $30–70 million range is defensible; the mid-point of roughly $40–50 million is where I'd anchor a working estimate without better disclosure of private assets.
How He Built the Wealth: Career Path and Income Sources
Cherington's career follows a fairly classic private equity trajectory, but with an unusually long runway. His first job out of his University of Chicago MBA was at Credit Suisse in municipal finance. He then worked at Lochridge and Company, spent time with the Vietnam Fund operating in Hanoi and Saigon, and eventually built his own investment platforms. He founded Intervale Capital in 2006, a firm focused on energy and industrial markets, before co-founding Ara Partners in 2017 with a specific mission to decarbonize the industrial economy.
By the numbers, 25+ years of private equity experience, investments in 60+ companies, and the founding of ten private equity firms collectively describe someone whose income has been driven by management fees, carried interest (the share of profits general partners receive, typically 20% of fund returns above a hurdle rate), and co-investment returns. When Ara Partners closed a $400 million fund, that milestone alone implies annual management fees in the range of $4–8 million to the firm overall, with Cherington as co-head taking a meaningful share. Across multiple fund cycles over two decades, carried interest payouts from successful exits would represent the single largest component of accumulated wealth for someone in his position.
On top of private equity income, his SEC-disclosed activity shows active personal investing. In June 2025, he purchased 21,241,163 shares of ERNA for approximately $2.2 million. In February 2026, he bought another 4,000,000 shares at $0.50 per share, a $2 million commitment. These are not passive index fund plays; they are direct, concentrated bets on a specific biotech company, which tells you something about his investment style and available liquidity.
Documented Assets, Investments, and Business Interests

The clearest window into Cherington's assets comes from SEC filings tied to Eterna/Ernexa Therapeutics. A beneficial ownership table in SEC-archived documents lists Charles Cherington with 6,779,440 shares, plus additional shares tied to warrants and convertible instruments. His total beneficial ownership percentage has been reported at various points between roughly 19.99% and 45.7% depending on how diluted or fully diluted share counts are used. The SEC Form 4 filing confirms him as a 10% owner subject to Section 16 reporting, which applies to anyone holding more than 10% of a public company's shares.
- Equity stake in Eterna/Ernexa Therapeutics (ERNA): Multiple tranches purchased in 2025 and 2026, with disclosed share counts in the tens of millions at sub-$1 per share prices
- Managing partner economics at Ara Partners: A share of management fees and carried interest from a firm that has deployed capital from at least one $400 million fund
- Conservation land in Vermont: Described as the largest private owner of conservation land in the state, though exact acreage and valuation are not publicly disclosed
- Prior firm interests: Residual economics from Intervale Capital (founded 2006) and other earlier PE vehicles
- Previous firm registration: Cherington Capital LLC in Cambridge, MA, per SEC IAPD records, suggesting a prior personal investment vehicle
- Charles S Cherington Trust: A related nonprofit entity with net assets of approximately $2.39 million and zero liabilities as of the fiscal year ending June 2025 (per ProPublica Form 990-PF data)
The Vermont conservation land is a genuinely interesting asset because conservation land held by private owners can carry significant appraised value while also potentially generating tax benefits through conservation easements. Without a disclosed purchase price or appraised value, it's hard to assign a number, but it is almost certainly a meaningful asset for someone described as the state's largest private holder.
Liabilities and Factors That Could Shrink the Estimate
The honest answer here is that no major publicly documented liabilities appear to exist. The SEC IAPD profile for Charles Reed Cherington, registered under ARA GC PARTNERS, LLC, includes a disclosures section that covers regulatory actions, bankruptcies, arbitrations, and civil or criminal proceedings. The New York Department of Public Service document “EXHIBIT A - Organizational Charts” includes references to Ara Energy Fund entities and lists “Charles Cherington,” supporting the linkage between his governance role and these regulated/official filings Ara Energy Fund entities and lists “Charles Cherington”. No significant adverse disclosures appear in the public record as of mid-2026. The Charles S Cherington Trust also reports zero liabilities on its Form 990-PF for fiscal year ending June 2025.
That said, several factors create legitimate downside risk to the headline estimates. His ERNA holdings are in a small-cap biotech stock trading at very low per-share prices. Biotech stocks at that price level carry high volatility and liquidity risk; the paper value of tens of millions of shares can evaporate quickly if the company underperforms. Private equity fund economics also depend entirely on exit performance: carried interest is not realized until portfolio companies are sold or go public, meaning a significant portion of his expected wealth may be tied to future outcomes rather than current cash. Additionally, running multiple private equity firms and maintaining large conservation land holdings implies ongoing operational costs, employee compensation, and property taxes that represent real cash outflows.
How Net Worth Estimates Are Calculated (and Why They Disagree)
Net worth estimates for private investors like Cherington are assembled from fragments, not complete financial disclosures. Here's what goes into them and where the disagreements come from.
| Source Type | What It Reveals | Limitation |
|---|---|---|
| SEC Form 4 filings | Exact share counts and transaction prices for public company holdings | Only covers publicly traded equity; misses all private assets |
| SEC IAPD (investment adviser registration) | Firm affiliations, prior firms, regulatory history | Does not disclose personal wealth or income |
| Beneficial ownership tables (proxy/ARS filings) | Total shares including options, warrants, convertibles | Can overstate 'owned' assets if instruments aren't yet exercised |
| Aggregator platforms (Benzinga, QuiverQuant) | Quick net worth estimates based on disclosed equity | Methodology varies; often capture only a single asset class |
| Nonprofit Form 990-PF (ProPublica) | Trust net assets, liabilities, grants | Only covers the charitable entity, not personal wealth |
| Press releases and firm websites | Fund sizes, career history, co-founder status | Marketing documents; don't disclose personal compensation |
The gap between Benzinga's $71.1 million and QuiverQuant's $28.1 million almost certainly comes down to how each platform treats beneficial ownership. If Benzinga is counting all shares Cherington could potentially own (including warrants and convertible instruments), while QuiverQuant counts only directly owned common shares, a $40+ million difference isn't surprising for a stake in a company with hundreds of millions of shares outstanding at low prices. Neither platform has access to his private equity economics, real estate appraisals, or personal bank accounts. This is why treating any single published figure as definitive is a mistake. If you came here looking for Felix Charney net worth, note that the same reporting limitations can make published estimates vary widely.
How to Verify the Number Yourself

If you want to do your own due diligence on Cherington's net worth rather than relying on aggregator estimates, here's a practical research checklist that covers the most useful public sources. If you also want to evaluate the claim behind the charlatans net worth discussions, focus on the same disclosed assets and cross-check them against the newer filings Cherington's net worth.
- SEC EDGAR full-text search: Search 'Cherington' to pull all Form 4 filings and beneficial ownership disclosures tied to ERNA and any other public companies. This gives you the most current and granular equity picture.
- SEC IAPD: Look up 'Charles Reed Cherington' at adviserinfo.sec.gov to confirm firm affiliations, registration history with ARA GC PARTNERS and Cherington Capital LLC, and check the disclosures tab for any regulatory or legal flags.
- Ara Partners website (arapartners.com): The team page and press releases document fund sizes, co-founder status, and investment themes. Fund size is the starting point for estimating management fee income.
- ProPublica Nonprofit Explorer: Search 'Charles S Cherington Trust' to access Form 990-PF filings, which show the trust's assets, liabilities, and grantmaking activity over multiple years.
- Nasdaq and QuiverQuant insider transaction pages: These aggregate SEC Form 4 data and display transaction history with dates, prices, and share counts in a readable format, making it easier to track ERNA purchases over time.
- The Conservation Fund board page: Confirms his identity, role, and the Vermont land conservation connection, which helps disambiguate him from the historical academic figures with similar names.
- New York Department of Public Service filings: The Ara Energy Fund organizational charts filed with NY DPS provide an additional documentary link between Cherington and specific fund entities for anyone tracing business structure.
Where Things Stand Today
As of mid-2026, Charles Cherington is an active investor running Ara Partners, which he co-heads with Troy Thacker from offices in Boston. He continues to make sizable personal investments in Ernexa Therapeutics, with purchases documented as recently as February 2026. His career places him firmly in the category of wealthy private equity professionals whose real net worth is largely opaque to the public: the disclosed equity positions give you a floor, the private fund economics give you reason to believe the ceiling is meaningfully higher, and the conservation land adds a hard-to-appraise but real asset layer on top. If you are comparing this figure to Richard Charlton net worth, treat any numbers you see as separate from Charles Reed Cherington's disclosures and career profile.
Compared to other figures tracked on this site, Cherington's wealth profile is less about celebrity or public visibility and more about the compounding economics of two-and-a-half decades in private equity. The story of how he built it, from a first job in municipal finance at Credit Suisse to co-founding ten firms and deploying capital across 60+ companies, is actually a more useful lens for understanding the wealth than any single published number. For readers who want the most defensible working figure today: $30–50 million is where the evidence comfortably lands, with reasonable upside to $70+ million if private equity realizations and land valuations are factored in. If you're specifically comparing Wayne Charvel net worth figures, it helps to use the same approach and be cautious about how different sources treat private holdings and dilution.
FAQ
Does being listed as a 10% owner in SEC filings mean his net worth is exactly that value?
No. The 10% owner language under SEC Section 16 is a disclosure threshold, but it does not mean every net worth estimate should be multiplied from that single line item. Beneficial ownership percentages can shift based on fully diluted share counts, and the value can also be affected by options or convertible instruments even if the “10% owner” label stays the same.
Why do some net worth sites show very different numbers for the same Cherington stake?
Not necessarily. Aggregators may treat concentrated biotech stakes differently by including options, warrants, convertible securities, or using fully diluted share counts. If you want the “floor,” focus on directly owned common shares, while treating any additional instrument exposure as upside that could dilute or be worth less if conversion terms are unfavorable.
How fragile is the valuation of his ERNA/Ernexa holdings at low per-share prices?
A biotech position does not behave like a diversified public portfolio. Even if the share-count math looks large, mark-to-market value can swing quickly because of binary clinical results, thin trading volumes at low prices, and volatility around reverse splits or financing events.
When estimating value, should I add common shares and warrant or convertible shares together?
They can, but only if you have clarity on whether the reported share totals include instruments that are not yet exercisable, or conversion ratios that change with future financing. To avoid double counting, compare the exact securities listed in each Form 4 and beneficial ownership table, then separate “common owned” from “warrants/convertible” when you build a valuation.
Why can private equity “income” not translate into the same year’s net worth estimate?
Carried interest is not the same as realized wealth. A large portion of private equity compensation becomes net worth only after portfolio exits, and some earnings may be deferred, subject to clawbacks, or dependent on fund-level performance hurdles. That means a person can look “rich” in paper holdings while cash outcomes arrive later.
What fund stage matters most for whether his net worth is high or likely to rise?
Management fees, carried interest, and co-investment returns can all contribute, but they do not equal identical cash flows. If you are sanity-checking, ask whether the fund life stage is early (more fees, fewer exits) or mature (more realizations). For older funds, carried interest realizations are more likely to show up in net worth through disclosed liquid holdings and structured assets.
If public records show few liabilities, what are the most realistic ways net worth could still be overstated?
Downside exists even without documented liabilities. The most practical risk is liquidity, because selling concentrated biotech shares can move the price or be restricted by contract or trading windows. Conservation land can also add ongoing costs like property taxes, insurance, and maintenance, even if it offers potential tax benefits.
How do I make sure I am looking at Charles Reed Cherington and not a different Charles R. Cherington?
Yes. The article notes multiple people with similar names appear in public records. If you are researching independently, match at least two identifiers such as the Belmont base, Ara Partners involvement, and the specific SEC ticker ERNA, then disregard records tied to different birth years or unrelated career descriptions.
What is a practical method to reconcile a “floor” estimate versus a “maximum/fully diluted” estimate?
A discrepancy can happen if one platform uses “potential maximum” ownership (including fully diluted assumptions) while another uses only shares directly held. A quick decision aid is to treat the lower figure as the conservative minimum, then apply a separate, clearly marked uplift for warrants or convertibles only if those instruments are actually exercisable and in-the-money at current prices.
What should I look at in SEC transactions to improve beyond an aggregator net worth number?
You can. The strongest next step is to pull the most recent SEC Form 4 filings for ERNA and list each transaction (date, number of securities, and consideration), then check whether the buys align with any later sale activity. If purchases cluster but no disposals appear, that suggests ongoing conviction and potentially meaningful unrealized gains, but it still does not guarantee net worth because liquidity and valuation remain uncertain.
Does “zero liabilities” on a trust filing mean his overall net worth has no debt?
Typically, yes. Form 990-PF reporting for a trust can show liabilities, but it might not include all personal assets held outside the trust, and net worth is broader than trust net assets. So a “zero liabilities” read on a trust does not automatically mean the individual has no obligations elsewhere.
How should I compare his net worth to other investors tracked on the site (like other “Char-” entries) fairly?
It is usually more useful to compare the net worth methodology, not just the final number. For example, if two people share similar biotech exposure, the same beneficial-ownership versus fully diluted treatment can create artificial gaps. If one person’s wealth is more driven by private equity realizations versus paper holdings, the valuation timing risk will differ.

